Bhatt، نويسنده , , Jignesh and Subbaiah، نويسنده , , Gunta and Kambli، نويسنده , , Sandeep R Shah، نويسنده , , Bhavin and Nigam، نويسنده , , Samita and Patel، نويسنده , , Mehul and Saxena، نويسنده , , Ashish and Baliga، نويسنده , , Ashok and Parekh، نويسنده , , Hetal and Yadav، نويسنده , , Gunvat، نويسنده ,
A rapid and sensitive liquid chromatography–tandem mass spectrometry (LC–MS/MS) method has been developed and validated for the estimation of rivastigmine in human plasma. Rivastigmine was extracted from human plasma by using solid-phase extraction technique. Zolpidem was used as the internal standard. A Betabasic-8 column provided chromatographic separation of analytes followed by detection with mass spectrometry. The mass transition ion-pair was followed as m/z 251.20 → 206.10, 86.20 for rivastigmine and m/z 308.10 → 235.10 for zolpidem. The method involves a rapid solid-phase extraction from plasma, simple isocratic chromatographic conditions and mass spectrometric detection that enables detection at sub-nanogram levels. The proposed method has been validated for a linear range of 0.2–20.0 ng/ml with a correlation coefficient ≥0.9988. The intra-run and inter-run precision and accuracy were within 10.0%. The overall recoveries for rivastigmine and zolpidem were 86.28% and 87.57%, respectively. The total run time was 2.0 min. The developed method was applied for the determination of the pharmacokinetic parameters of rivastigmine following a single oral administration of a 3 mg rivastigmine capsule in 20 healthy male volunteers.